UARK 2003-33, Total Therapy III

PHASE2CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

Velcade

Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.

DRUG

Thalidomide

Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00081939 - UARK 2003-33, Total Therapy III | Biotech Hunter | Biotech Hunter